Judge Kennelly Reversed $140.1 million AndroGel Verdict

Judge Kennelly Reversed $140.1 million AndroGel Verdict

Introduction

Testosterone Replacement Therapy (TRT) provider AbbVie Inc. recently managed to overturn a $140.1 million verdict for a man who accused the company of hiding the adverse effects of its TRT drug AndroGel, which caused him a cardiac arrest.

In reversing the October verdict Judge Matthew Kennelly stated the jury's findings on Tennessee resident's claims are inconsistent with its decision to find AbbVie not liable on another claim as both involved determining if AndroGel was harmful and induced his heart attack. Judge Kennelly wrote, “When this happens, the court cannot accept one of the two inconsistent verdicts while discarding the other; both of them have to go". AbbVie Inc faces more than 4,500 lawsuits claiming the company did not forewarn about the risks of heart attacks, strokes, and blood clots that could occur from using AndroGel.

Testosterone Replacement Therapy lawsuits are centralized before U.S. District Judge Matthew Kennelly in the Northern District of Illinois as a part of federal multidistrict litigation (MDL No. 2545; In Re: Testosterone Replacement Therapy Products Liability Litigation).